Deposition of protein aggregates is the hallmark of an increasing number of diseases, including neurodegenerative disorders as well as type II diabetes, peripheral amyloidoses and cardiovascular disease. How exactly the amyloid deposits are linked with cytotoxicity and neuronal death has remained enigmatic. We are using biochemical and cell biological approaches to gain insight into the molecular basis of neurodegenerative disorders associated with aberrant protein folding, such as Alzheimer’s, Parkinson’s and Huntington’s disease.

Our long-term goal is to understand the mechanisms by which protein misfolding and aggregation cause cellular toxicity and how molecular chaperones and cellular stress response pathways are involved in this process.

To maintain protein homeostasis (or proteostasis) – the state of proteome balance – mammalian cells must ensure that more than 10,000 different proteins fold and assemble efficiently upon synthesis and preserve their functionally active states in a wide range of environmental and metabolic conditions. Cellular proteostasis is controlled by a complex network of factors, including molecular chaperones, proteases, and their regulators. Misfolded proteins are recognized and either refolded, degraded, or sequestered to distinct cellular sites. However, when these proteostasis machineries become compromised, as is increasingly the case during aging, aberrant proteins tend to accumulate as toxic aggregate species. This process is associated with numerous neurodegenerative diseases and other disorders, however the questions of what features make an aggregate toxic and how an aggregate harms the cell are still unresolved.
The functional proteostasis network antagonizes the build-up of aggregates or strives to neutralize their toxic effects. This may be achieved by fundamentally different strategies. Prevention of aggregation is a primary function of molecular chaperones and is achieved by binding of aggregation-prone folding intermediates, followed by their refolding or degradation. Pre-existing aggregates may be shielded by chaperones to block harmful interactions or may be removed by disaggregation or autophagy. Alternatively, toxic aggregate species, may be actively converted into large inclusion bodies, thereby reducing their reactive surfaces for toxic interactions with cellular components, or be temporarily stored in liquid like compartments like the nucleolus.

The proteostasis machinery in the nucleus differs from that of the cytosol in that no protein synthesis occurs in this compartment. In contrast to protein transport into the ER or mitochondria, the nuclear pore complexes allow the import of proteins in their folded and assembled states. Besides specific roles in histone remodeling, the nuclear chaperone machinery is therefore mainly involved in conformational protein maintenance and in the degradation of misfolded proteins. During stress, import of most proteins into the nucleus is reduced but additional chaperones and proteasome complexes enter using specific import factors. Diseases associated with protein aggregation, such as Huntington’s Disease are often characterized by the presence of intranuclear inclusions. This may be explained by recent observations that misfolded cytosolic proteins, including mutants of huntingtin, are transported into the nucleus for proteasomal degradation. When the nuclear proteostasis capacity is exhausted, misfolded proteins may then form intranuclear inclusions. Because the autophagic machinery has no access to the nucleus, perhaps the only possibility to remove these aggregates is to transport them to the cytosol after disassembly of the nuclear envelope during mitosis. This would help to explain why postmitotic cells such as neurons are more vulnerable to intra- nuclear inclusions.

Mechanisms to counteract toxicity of nuclear aggregates
Mechanisms to counteract toxicity of nuclear aggregates. Summary of suggested pathways to handle toxic aggregates. Note that the identity of the toxic aggregate species (red) is still unknown.
Relevance

Understanding protein quality control to combat protein misfolding diseases

Over 40 million people worldwide suffer from dementia, a neurological syndrome which affects memory, thought, and the ability to perform everyday activities. By 2050, this number is expected to triple. Especially the industrialized high-income countries with their aging populations will face tremendous personal and economic consequences if no effective treatments are developed.
Dementia is predominantly caused by different neurodegenerative diseases. These dementias are the fastest growing disease group among the leading causes of death in high-income countries, and are already the most expensive disease class in the Netherlands: 9,1 billion Euros or 10,3% of the national health care budget in 2017.

Although the symptoms of neurodegenerative diseases vary, many of them share one feature: the accumulation of protein aggregates. Preventing protein misfolding and aggregation is therefore a promising strategy for tackling these diseases. Progress in this regard is especially important: despite the enormous suffering caused by these disorders, and the huge efforts made by academic researchers and the pharmacological industry, there is still no successful therapy for this group of devastating diseases.

An important first step in the prevention or delay of the onset of aggregate-related diseases is to understand the cellular processes that lead to the formation of aggregates, and to identify the endogenous factors that prevent their formation.

Our work consists of essential, basic research that aims at addressing these points. The scientific discoveries made through our research will expand the field of protein quality control and enrich the scientific field at large with new mechanisms, drug targets and interventions.

Research Interests

  • While quality control in the cytoplasm and the endoplasmic reticulum has been studied extensively, knowledge of the nuclear quality control machinery is limited. What we do know is that nuclear accumulation of protein aggregates is the hallmark of a number of neurodegenerative disorders, including amyotrophic lateral sclerosis and Huntington’s disease. Despite the urgent need for treatment, the identity of the toxic nuclear aggregate species and the specific mechanism by which they harm cells remain unknown. Researchers have long treated protein quality control in the nucleus and the cytoplasm as identical processes. However, our recent work has demonstrated that the subcellular environment strongly influences aggregation and toxicity of misfolded proteins. It is still poorly understood what parts of the nuclear quality control machinery cause this difference, and what parts of the nucleus are vulnerable to aggregates. In this project we plan to identify the factors that ensure the correct handling of misfolded proteins in the nucleus of healthy cells, and establish why these factors fail during ageing and disease. We will characterize the components of nuclear quality control machinery that interact with defective proteins, unravel the mechanisms of cytotoxicity caused by nuclear aggregates, and identify factors that can induce a protective response.
    We will identify those components of nuclear QC that can be targeted to prevent aggregation-mediated pathophysiology, and the pathways that enable cells to activate their protective mechanisms to delay the onset of degenerative diseases.

  • Intracellular protein aggregates of the microtubule-associated protein tau can be observed in Alzheimer’s disease. Recent studies have suggested that these aggregates have the ability to spread from cell to cell in a prion-like manner, which may drive disease progression. Preventing the transmission of aggregates therefore presents a possibility to slow down progression of the disease. We suggest to stop spreading by boosting the quality control network of the cells exposed to the aggregates. We hypothesize that this can prevent the amplification of aggregates inside cells when the cellular quality control network is not yet overwhelmed by the presence of large amounts of aggregates. This project aims to identify components of the cellular quality control machinery that can interfere with disease associated tau aggregates. We expect to identify novel factors that reduce amplification of intracellular tau seeds, and will represent potential drug targets.

Contact

Small profile photo of M.S. Hipp
Mark Hipp Head of Protein Quality Control in Health and Disease
Greetje Noppert Secretary - Section Molecular Cellbiology

University Medical Center Groningen (UMCG)
Department of Biomedical Sciences of Cells and Systems
Mark S. Hipp - Protein Quality Control in Health and Disease
Internal Zip code FB31
Antonius Deusinglaan 1
9700 AD Groningen
The Netherlands

Visiting Address
University Medical Center Groningen (UMCG)
Department of Biomedical Sciences of Cells and Systems
Antonius Deusinglaan 1
Building 3215, 5th floor, room 505-B
9713 AV Groningen
The Netherlands